Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

HB Investment

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 113
Average round size
info
The average size of a deal this fund participated in
$5M
Portfolio companies 100
Rounds per year 4.52
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.12
Exits 3
Key employees 2

Areas of investment

  • Biotechnology
  • Software
  • Medical
  • Health Care
  • Pharmaceutical
Summary

The leading representative office of defined VC is situated in the Seoul. The fund was located in Asia if to be more exact in South Korea.

The usual cause for the fund is to invest in rounds with 5 partakers. Despite the HB Investment, startups are often financed by KB Investment, Softbank Ventures Asia, Shinhan Capital. The meaningful sponsors for the fund in investment in the same round are KB Investment, TL Asset Management, Smilegate Investment. In the next rounds fund is usually obtained by Murex Partners, Bass Investment, Shinhan Bank.

Besides them, we counted 2 critical employees of this fund in our database.

The real fund results show that this VC is 6 percentage points less often commits exit comparing to other companies. The top activity for fund was in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually.

Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most popular fund investment industries, there are Medical Device, Medical. Among the various public portfolio startups of the fund, we may underline True Balance, Uberple, Siksin The fund has exact preference in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the country of its foundation and the country of its the most frequent investments - South Korea.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ArcAngels Auckland, Auckland, New Zealand
Capitole Angels France, Midi-Pyrenees, Toulouse
CapXM -
China Evergrande Group China, Guangdong, Guangzhou
Formula Group Delhi, India, New Delhi
Fuguo Investment China, Guangdong, Shenzhen
Fullshare Holdings China, Hong Kong, Hong Kong Island
GE Appliances Kentucky, Louisville, United States
GMO VenturePartners Chiyoda, Japan
Handmade Ventures California, San Mateo, United States
Jasmine Social Investments -
Masthead Venture Partners Danvers, Massachusetts, United States
Moquin Capital -
Ontario Scale-Up Vouchers Program (OSVP) -
Qbera Ventures -
Sazerac Company Louisiana, Metairie, United States
Tonic Fund -
Tweed Renaissance Investors Capital -
Vaizra Capital New York, New York, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Lucas

Medical Device
Software
02 Oct 2024 Yeoksamdong, Seoul-t'ukpyolsi, South Korea

Unastella

Aerospace
Manufacturing
$16M25 Sep 2024 Seoul, Seoul-t'ukpyolsi, South Korea

Creators Network

Art
Service Industry
$3M22 Jul 2024 -

Ground Seesaw

Art
Events
Media and Entertainment
$9M11 Jul 2024 Seoul, Seoul-t'ukpyolsi, South Korea

AITRICS

Analytics
Artificial Intelligence
Health Care
Information Technology
$23M21 Mar 2024 Seocho, Seoul-t'ukpyolsi, South Korea

Driving Teacher

App Marketing
Training
12 May 2023 Seoul, Seoul-t'ukpyolsi, South Korea

Law&Good

Consulting
Legal
Professional Services
$6M27 Jan 2023 South Korea, Gangwon-do, South Korea

Yipscell

Biotechnology
Consumer Research
Therapeutics
$11M28 Dec 2022 Seocho, Seoul-t'ukpyolsi, South Korea

Oncosoft

Health Diagnostics
Software
Software Engineering
$2M22 Aug 2022 Seoul, Seoul-t'ukpyolsi, South Korea

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent HB Investment?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 113
Average round size 5M
Rounds per year 4.52
Peak activity year 2021
Lead investments 4
Follow on index 0.12
Exits 3
Group Appearance index 0.63

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Lucas

Medical Device
Software
02 Oct 2024 Yeoksamdong, Seoul-t'ukpyolsi, South Korea

Unastella

Aerospace
Manufacturing
$16M25 Sep 2024 Seoul, Seoul-t'ukpyolsi, South Korea

Creators Network

Art
Service Industry
$3M22 Jul 2024 -

Ground Seesaw

Art
Events
Media and Entertainment
$9M11 Jul 2024 Seoul, Seoul-t'ukpyolsi, South Korea

AITRICS

Analytics
Artificial Intelligence
Health Care
Information Technology
$23M21 Mar 2024 Seocho, Seoul-t'ukpyolsi, South Korea

Driving Teacher

App Marketing
Training
12 May 2023 Seoul, Seoul-t'ukpyolsi, South Korea

Law&Good

Consulting
Legal
Professional Services
$6M27 Jan 2023 South Korea, Gangwon-do, South Korea

Yipscell

Biotechnology
Consumer Research
Therapeutics
$11M28 Dec 2022 Seocho, Seoul-t'ukpyolsi, South Korea

Oncosoft

Health Diagnostics
Software
Software Engineering
$2M22 Aug 2022 Seoul, Seoul-t'ukpyolsi, South Korea
Crunchbase icon

Content report

The following text will be sent to our editors: